Discounted Cash Flow (DCF) Analysis Levered

Magenta Therapeutics, Inc. (MGTA)

$1.41

-0.03 (-2.08%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 1.41
Beta 2.076
Diluted Shares Outstanding 54.95
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 13.497
Total Debt -
Total Equity 77.48
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF ----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -131.65
Equity Value -
Shares Outstanding 54.95
Equity Value Per Share -